No association between use of angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID‐19 in the COvid MEdicaTion (COMET) study

Study (n=4870; 17.4% ACEi users; 15.6% ARB users) found no association with ACEi and composite endpoint (OR 0.94), mortality (1.03) or ICU admission (0.96). Similarly, no association observed between ARB and composite endpoint (1.09), mortality (1.12) or ICU admission (1.21).

Source:

British Journal of Clinical Pharmacology